Li Kang Biomedical Co., Ltd. manufactures and sells supplements, cosmeceutials, and hygienic tea drinks. More Details
Flawless balance sheet with proven track record.
Share Price & News
How has Li Kang Biomedical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 6242 is more volatile than 75% of TW stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: 6242's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of TW stocks.
7 Day Return
TW Personal Products
1 Year Return
TW Personal Products
Return vs Industry: 6242 exceeded the TW Personal Products industry which returned -5.5% over the past year.
Return vs Market: 6242 exceeded the TW Market which returned 48.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Li Kang Biomedical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StLi Kang Biomedical (GTSM:6242) Has Some Way To Go To Become A Multi-Bagger
3 months ago | Simply Wall StIs Li Kang Biomedical Co., Ltd. (GTSM:6242) A Smart Choice For Dividend Investors?
Is Li Kang Biomedical undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 6242 (NT$55) is trading below our estimate of fair value (NT$63.72)
Significantly Below Fair Value: 6242 is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: 6242 is poor value based on its PE Ratio (16.3x) compared to the TW Personal Products industry average (15.5x).
PE vs Market: 6242 is good value based on its PE Ratio (16.3x) compared to the TW market (17.5x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 6242's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 6242 is overvalued based on its PB Ratio (2.4x) compared to the TW Personal Products industry average (2.2x).
How is Li Kang Biomedical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Household industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Li Kang Biomedical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Li Kang Biomedical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6242 has high quality earnings.
Growing Profit Margin: 6242's current net profit margins (15.6%) are higher than last year (13.5%).
Past Earnings Growth Analysis
Earnings Trend: 6242's earnings have declined by 2.5% per year over the past 5 years.
Accelerating Growth: 6242's earnings growth over the past year (27.3%) exceeds its 5-year average (-2.5% per year).
Earnings vs Industry: 6242 earnings growth over the past year (27.3%) exceeded the Personal Products industry 4.7%.
Return on Equity
High ROE: 6242's Return on Equity (14.4%) is considered low.
How is Li Kang Biomedical's financial position?
Financial Position Analysis
Short Term Liabilities: 6242's short term assets (NT$268.4M) exceed its short term liabilities (NT$120.5M).
Long Term Liabilities: 6242's short term assets (NT$268.4M) exceed its long term liabilities (NT$41.7M).
Debt to Equity History and Analysis
Debt Level: 6242's debt to equity ratio (7.5%) is considered satisfactory.
Reducing Debt: 6242's debt to equity ratio has reduced from 46.2% to 7.5% over the past 5 years.
Debt Coverage: 6242's debt is well covered by operating cash flow (274.2%).
Interest Coverage: 6242 earns more interest than it pays, so coverage of interest payments is not a concern.
What is Li Kang Biomedical current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 6242's dividend (5.09%) is higher than the bottom 25% of dividend payers in the TW market (2.04%).
High Dividend: 6242's dividend (5.09%) is in the top 25% of dividend payers in the TW market (5.01%)
Stability and Growth of Payments
Stable Dividend: 6242 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 6242's dividend payments have increased, but the company has only paid a dividend for 5 years.
Current Payout to Shareholders
Dividend Coverage: At its current payout ratio (82.9%), 6242's payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Li Kang Biomedical has no CEO, or we have no data on them.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Li Kang Biomedical Co., Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: Li Kang Biomedical Co., Ltd.
- Ticker: 6242
- Exchange: TPEX
- Founded: 1982
- Industry: Personal Products
- Sector: Household
- Market Cap: NT$1.210b
- Shares outstanding: 22.20m
- Website: https://www.likangbio.com
Number of Employees
- Li Kang Biomedical Co., Ltd.
- No. 29, Huangong Road
- Yongkang District
- Tainan City
Li Kang Biomedical Co., Ltd. manufactures and sells supplements, cosmeceutials, and hygienic tea drinks. It also offers tourism factory management, tourism factory management consulting, and telemarketing ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/18 08:56|
|End of Day Share Price||2021/06/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.